Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT 1A partial agonists
Compounds with combined norepinephrine reuptake inhibitor (NRI) and serotonin 1A (5-HT 1A) partial agonist pharmacology may offer a new therapeutic approach for treating symptoms of neuropsychiatric disorders including ADHD, depression, and anxiety. Herein we describe the design and optimization of...
Saved in:
Published in | Bioorganic & medicinal chemistry letters Vol. 21; no. 2; pp. 865 - 868 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Ltd
15.01.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Compounds with combined norepinephrine reuptake inhibitor (NRI) and serotonin 1A (5-HT
1A) partial agonist pharmacology may offer a new therapeutic approach for treating symptoms of neuropsychiatric disorders including ADHD, depression, and anxiety. Herein we describe the design and optimization of novel chemical matter that exhibits favorable dual NRI and 5-HT
1A partial agonist activity. Lead compounds in this series were found to be devoid of activity at the dopamine transporter and were shown to be brain penetrant with high receptor occupancy. |
---|---|
ISSN: | 0960-894X 1464-3405 |
DOI: | 10.1016/j.bmcl.2010.11.066 |